Second Sight

You might remember the Argus II implant from when it first gained market approval in the US back in 2013. The ambitious prosthesis is back, with researchers now looking to utilize the technology to treat patients with dry age-related macular degeneration (AMD).

The Argus II "bionic eye" has received U.S. market approval from the Food and Drug Administration (FDA).

Scientists have used a retinal prosthesis to stream visual braille patterns directly onto a blind test subject's retina.

Second Sight has published interim results of a clinical trial of its Argus II Retinal Prosthesis showing encouraging results in blind patients suffering severe retinitis pigmentosa (RP).

The Argus II Retinal Implant from California-based company Second Sight has become the first retinal prosthesis for treatment of the blind approved for sale in Europe.

Clinical trials of the Argus II, the second-generation retinal implant developed by Second Sight Medical Products Inc, are encouraging, bringing hope to thousands of people with advanced retinal disease.

Enrollment is complete for the Phase I trial of the electronic retinal implant known as The Argus II - a device which restores a basic level of sight using an external camera mounted in eyeglasses linked to a tiny array of 60 electrodes attached to the retina.

February 19, 2007 Patients who have gone blind are a step closer to perhaps one day regaining some of their sight with the news that the United States FDA ha